Top Hedge Fund News, Member Posts, Hedge Fund Daily Indices and more!

2yrs ago Hedge Fund hedgeweek Views: 320

Enfusion appoints Chief Technology Officer

Submitted 21/07/2021 - 9:09am

Enfusion, a provider of cloud-based investment management software and services, has promoted Dan Groman from Co-Head of Technology to Chief Technology Officer (CTO). 

In his role, Groman will lead the overall Software Development, Product Management, IT and Security teams in driving strategic technology development and innovation to maximize Enfusion's impact as a solutions partner for institutional investment managers and hedge funds.
 
"We are thrilled to have Dan step into this new role as we embark on the next phase of our growth and innovation roadmap," says Thomas Kim, CEO of Enfusion. "From day one, Dan's unmatched enthusiasm for technology has allowed him to engineer value-added solutions that solve our clients' biggest challenges in a meaningful way instead of simply creating widgets. He has an established reputation for being a client-first, forward thinker with deep product expertise. As CTO, Dan will continue to accelerate the innovation of our cloud-native platform and services to not only help our clients solve the operational challenges they face today, but to prepare them for a successful and scalable future."                                                     
 
Groman joined Enfusion in 2016 as a software developer and was an integral force behind building out Enfusion's data warehouse, coding solutions and directing initiatives in all areas of software engineering, including leading the proof of concept for the firm's visual analytics platform and building out the engineering training program. Since then, he has worked closely with the founding partners to manage Enfusion's software development teams and lead the IT and Security teams globally. Prior to joining Enfusion, Groman was a Systems Engineer at CME Group working on the exchange's systems infrastructure. Groman began his career in middle- and back-office operations for institutional managers, holding positions at Northern Trust Hedge Fund Services and King Street Capital Management.
 
"Enfusion brings a truly differentiated approach to investment management technology and services and I am honored to be leading a stellar team of technologists and product managers who are dedicated to taking Enfusion to the next level with our robust, reliable and risk-proofed solution," says Groman. "Enfusion's pioneering history in building agile cloud-native SaaS solutions on one dataset, well before 'cloud' was mainstream, has been a big inspiration for me. I look forward to building on that foundation, turning cutting-edge technology into a strategic asset for our clients and continuing to bring efficiency to investment workflow for fund managers around the world."
 
Groman's promotion to CTO comes after a record period of growth for Enfusion. The firm signed 160 new fund managers to the platform in 2020 and experienced triple-digit client growth year-over-year in APAC. Enfusion presently serves more than 600 clients from nine global offices.
 

Like this article? Sign up to our free newsletter Related Topics Moves & Appointments

Today's Hedge Fund Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.